Navidea biopharmaceuticals announces nih grant award to uc san diego for clinical study evaluating tc99m tilmanocept as a kidney imaging agent

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the granting of a national institutes of health (“nih”) award to the university of california san diego school of medicine for the proposal entitled, “renal molecular imaging of mesangial cell function with tc-99m-tilmanocept.” the award (project number: 1r01dk127201-0
NAVB Ratings Summary
NAVB Quant Ranking